Janney Montgomery Scott
EGRX

Janney Montgomery Scott’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Janney Montgomery Scott’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,661
Closed -$323K – 2080
2018
Q3 		$323K Buy
+4,661
New +$353K ﹤0.01% 1672
2018
Q2 		– Sell
-12,376
Closed -$652K – 2061
2018
Q1 		$652K Buy
+12,376
New +$720K 0.01% 1186

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janney Montgomery Scott's EGRX Position: Q4 2018 in Review

Janney Montgomery Scott sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2018, closing a stake of 4,661 shares — an estimated $323K sold.

Janney Montgomery Scott first reported a position in EGRX in Q1 2018 and held it in 2 quarters. The position peaked at $652K in Q1 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q4 2018.

  • Janney Montgomery Scott reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Janney Montgomery Scott sold 4,661 Eagle Pharmaceuticals, Inc. shares in Q4 2018, an estimated $323K.
  • Janney Montgomery Scott first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2018 and held it in 2 quarters.
  • Janney Montgomery Scott's Eagle Pharmaceuticals, Inc. position peaked at $652K in Q1 2018.
  • 182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2018.

Based on Janney Montgomery Scott's 13F filing for Q4 2018, filed 1 Feb 2019.